Treatments that regulate RARRES1 expression or activity could have utility in obesity, cholestatic liver disease, heart disease (in which RARRES1 expression is markedly decreased in hypertrophic and dilated cardiomyopathy) and cancers where lipogenesis is crucial for the progression of certain tumors [71]. Here, RARRES1 is linked to obesity due to melanocortin 4 receptor deficiency.